We understand how challenging it is to develop novel anticancer therapies. To facilitate your selection of the most active agent and the most appropriate dose regimens, Charles River offers years of experience in testing a variety of anti-cancer agents in a broad spectrum of in vitro and in vivo models. These include human tumor xenograft, syngeneic, metastatic, orthotopic, and genetically engineered models. These models can be augmented with the use of imaging technologies, such as small animal PET, MRI, CT, bioluminescence, and fluorescence. Other services available to help evaluate your novel cancer drug include angiogenesis, combination therapy, radiation therapy, biomarker assessment, pharmacokinetics, pharmacodynamics, histopathology, and immunohistochemistry. We regularly consult with our clients to develop detailed study protocols to meet their specific needs. Charles River’s global infrastructure, harmonized approach, and commitment to quality allow us to provide unparalleled service in the field of cancer research.
In vitro Efficacy Testing (IC50 Determination)
This service involves the evaluation of cell proliferation and cell death in response to test article administration in cultured tumor cell lines.
In vivo Cancer Pharmacology
Traditional evaluation in syngeneic and human tumor xenografts remains a mainstay of our evaluation services. These traditional models are supplemented with orthotopic, metastasis, and genetically engineered mouse tumor models. The addition of functional imaging technologies provides an integrated and quantitative correlation of efficacy with mechanism of action. Coupling our in vitro and imaging technologies with our selection of tumor models enables the validation of intended clinical biomarkers and the establishment of decision-making thresholds for the modulation of surrogate markers in Phase I and II clinical trials.
Additional Services